The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) closed at $0.24 down -4.27% from its previous closing price of $0.25. In other words, the price has decreased by -$4.27 from its previous closing price. On the day, 1.29 million shares were traded. ADAP stock price reached its highest trading level at $0.25 during the session, while it also had its lowest trading level at $0.2322.
Ratios:
For a deeper understanding of Adaptimmune Therapeutics Plc ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.79 and its Current Ratio is at 2.02.
On July 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $4.
On May 30, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $3.15.Scotiabank initiated its Sector Outperform rating on May 30, 2024, with a $3.15 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 17 ’25 when Norry Elliot sold 5,584 shares for $0.58 per share. The transaction valued at 3,243 led to the insider holds 7,510 shares of the business.
Lunger John sold 5,584 shares of ADAP for $3,243 on Jan 17 ’25. The Chief Patient Supply Officer now owns 7,510 shares after completing the transaction at $0.58 per share. On Jan 17 ’25, another insider, Bertrand William C JR, who serves as the Chief Operating Officer of the company, sold 5,584 shares for $0.58 each. As a result, the insider received 3,243 and left with 7,510 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 64195596 and an Enterprise Value of 374315968. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.35. Its current Enterprise Value per Revenue stands at 2.084 whereas that against EBITDA is -10.295.
Stock Price History:
The Beta on a monthly basis for ADAP is 2.23, which has changed by -0.7517949 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, ADAP has reached a high of $1.48, while it has fallen to a 52-week low of $0.20. The 50-Day Moving Average of the stock is -10.56%, while the 200-Day Moving Average is calculated to be -56.00%.
Shares Statistics:
For the past three months, ADAP has traded an average of 1.42M shares per day and 768620 over the past ten days. A total of 257.85M shares are outstanding, with a floating share count of 228.63M. Insiders hold about 11.33% of the company’s shares, while institutions hold 34.07% stake in the company. Shares short for ADAP as of 1749772800 were 4563895 with a Short Ratio of 3.21, compared to 1747267200 on 5834073. Therefore, it implies a Short% of Shares Outstanding of 4563895 and a Short% of Float of 2.09.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of Adaptimmune Therapeutics Plc ADR (ADAP) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.5 and -$0.5 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.49, with 1.0 analysts recommending between -$0.49 and -$0.49.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $11.18M this quarter.It ranges from a high estimate of $17M to a low estimate of $7.2M. As of the current estimate, Adaptimmune Therapeutics Plc ADR’s year-ago sales were $128.23MFor the next quarter, 8 analysts are estimating revenue of $14.4M. There is a high estimate of $18.4M for the next quarter, whereas the lowest estimate is $10.47M.
A total of 8 analysts have provided revenue estimates for ADAP’s current fiscal year. The highest revenue estimate was $63M, while the lowest revenue estimate was $38.18M, resulting in an average revenue estimate of $50.21M. In the same quarter a year ago, actual revenue was $178.03MBased on 9 analysts’ estimates, the company’s revenue will be $73.05M in the next fiscal year. The high estimate is $85M and the low estimate is $50.3M.
